People: Idenix Pharmaceuticals, Inc. (IDIX.O)

IDIX.O on Consolidated Issue listed on NASDAQ Global Market

3.00USD
9 Feb 2010
Price Change (% chg)

$0.05 (+1.69%)
Prev Close
$3.00
Open
--
Day's High
$3.00
Day's Low
$2.93
Volume
80,642
Avg. Vol
127,593
52-wk High
$5.96
52-wk Low
$1.81

view people for:

Summary

Name Age Since Current Position
Sommadossi, Jean-Pierre 53 2000 Chairman of the Board, President, Chief Executive Officer
Renaud, Ronald 40 2007 Chief Financial Officer, Treasurer
Weidenbruch, John 48 2006 Executive Vice President, General Counsel, Secretary
Standring, David 58 2007 Executive Vice President - Biology
Mayers, Douglas 55 2007 Executive Vice President, Chief Medical Officer
Fanning, Paul 51 2007 Senior Vice President - Human Resources
Hodgson, Thomas 67 Lead Director
Hockmeyer, Wayne 64 2002 Director
Cramb, Charles 62 2003 Director
Pelzer, Robert 55 2003 Director
Pollard-Knight, Denise 49 2003 Director
Projan, Steven 56 2009 Director
» Insider Trading

Biographies

Name Description
Sommadossi, Jean-Pierre Jean-Pierre Sommadossi, Ph.D. is Chairman of the Board, President, Chief Executive Officer of Idenix Pharmaceuticals, Inc. Dr. Sommadossi is the principal founder of Idenix and has served as the chairman of the board of directors since the inception and as president and chief executive officer since November 2000. During the period from November 1999 to November 2000, Dr. Sommadossi served as executive president and chief scientific officer. Dr. Sommadossi served as a professor of pharmacology, toxicology and clinical pharmacology and associate director of both the Center for AIDS Research and the Liver Center, University of Alabama at Birmingham School of Medicine from June 1992 to November 2000. Dr. Sommadossi took a sabbatical and then unpaid leave from the University of Alabama at Birmingham from November 1999 to November 2002. From 1996 to 1999, Dr. Sommadossi served on the Research Agenda Committee of the AIDS Clinical Trial Group. Dr. Sommadossi holds a Pharm.D. and Ph.D. in Pharmacology from the University of Marseilles, France.
Renaud, Ronald Ronald C. Renaud, Jr. has been appointed as Chief Financial Officer and Treasurer of Idenix effective June 29, 2007. Prior to joining Idenix, Mr. Renaud served as senior vice president, chief financial officer and treasurer of Keryx Biopharmaceuticals, Inc. from February 2006 to May 2007. Prior to joining Keryx, Mr. Renaud was a senior research analyst and global sector coordinator for JP Morgan Securities from May 2004 until February 2006, where he was responsible for the biotechnology equity research effort, covering all ranges of capitalized biotechnology companies. From 2001 to May 2004, Mr. Renaud held managing director posts at Charles Schwab & Co., SoundView Capital and Bear Stearns & Co., Inc., where he covered companies in the biotechnology and life sciences sectors. Mr. Renaud holds an M.B.A from the Marshall School of Business at the University of Southern California and a B.A. from St. Anselm College.
Weidenbruch, John John F. Weidenbruch has served as Executive Vice President, General Counsel and Secretary of Idenix Pharmaceuticals, Inc. since September 2006. Prior to joining Idenix, Mr. Weidenbruch served as vice president and general counsel at Abraxis BioScience Inc. from October 2005 until September 2006. Prior to joining Abraxis, Mr. Weidenbruch worked at Amgen Inc. from January 1995 until October 2005 where he held positions of increasing responsibility including senior director of law operations and senior associate general counsel of global commercial operations, leading a team of attorneys that, along with day-to-day guidance for commercial activities, supported the launch of new products. Mr. Weidenbruch holds a B.A. from Loyola College in Baltimore, Maryland and a J.D. from Georgetown University Law Center in Washington, D.C.
Standring, David David N. Standring, Ph.D. has served as Executive Vice President of Biology of Idenix Pharmaceuticals, Inc. since December 2007 and previously as senior vice president, biology from March 2006 to December 2007 and previously served as vice president, biology from March 2002 to March 2006 and as executive director of biology from September 2000 to March 2002. Prior to joining Idenix, Dr. Standring served from July 1999 to June 2000 as associate director, and from February 1998 to July 2000, Dr. Standring served as research fellow and then as associate director, virology department at Schering-Plough Research Institute, a division of Schering Plough Corporation, a pharmaceutical company. From November 1994 to January 1998, Dr. Standring served as group leader, hepatitis, virology department at Bristol-Myers Squibb Research Institute. From 1984 to 1994, Dr. Standring was on the faculty of the University of California at San Francisco. Dr. Standring holds a B.A. from St. John’s College, Oxford University and a Ph.D. in Bioorganic Chemistry from Harvard University.
Mayers, Douglas Douglas Mayers, M.D. has served as Executive Vice President and Chief Medical Officer of Idenix Pharmaceuticals, Inc. since January 2007. Prior to joining Idenix, from May 2001 until January 2007, Dr. Mayers was with Boehringer Ingelheim Pharmaceuticals, Inc., where he served as vice president, therapeutic area of virology and was responsible for the strategic coordination of all HIV and hepatitis clinical trials in phases I through IV. Prior to joining Boehringer Ingelheim, Dr. Mayers conducted clinical trials in HIV research during his seventeen years in the United States Navy and his subsequent three years as the head of infectious diseases with Henry Ford Hospital. Dr. Mayers completed his M.D. at the University of Pennsylvania.
Fanning, Paul Paul J. Fanning has served as Senior Vice President of Human Resources since December 2007 and as vice president, human resources from March 2004 to December 2007. Prior to joining Idenix, Mr. Fanning was employed by The Foxboro Company and its affiliates from 1984 to 2004, most recently as vice president, human resources at Invensys Process Systems from 2000 to 2004. Mr. Fanning holds an M.B.A. from Babson College and a B.S. from the University of Massachusetts.
Hodgson, Thomas Thomas R. Hodgson is Lead Director of Idenix Pharmaceuticals, Inc. Mr. Hodgson, who is retired, served most recently, from September 1990 to January 1999, as president and chief operating officer of Abbott Laboratories, a pharmaceutical company. From 1983 to 1990, Mr. Hodgson served as the president of Abbott International and from 1978 to 1983, Mr. Hodgson served as the president of the Hospital Products Division of Abbott Laboratories. Mr. Hodgson is a director of The Travelers Companies Inc. Mr. Hodgson holds a B.S. from Purdue University, an M.S. from the University of Michigan, an M.B.A. from Harvard Business School and an honorary doctorate degree in engineering awarded by Purdue University.
Hockmeyer, Wayne Wayne T. Hockmeyer is Director of Idenix Pharmaceuticals, Inc. Dr. Hockmeyer founded MedImmune, Inc., a biotechnology company, in April 1988 and served until October 2000 as the chief executive officer of MedImmune. In October 2000, Dr. Hockmeyer relinquished his position as chief executive officer and served as chairman of the board of directors of MedImmune, Inc. until June 2007 and from 2002 to 2007, as president of MedImmune Ventures, Inc., a wholly owned subsidiary of MedImmune, Inc. Dr. Hockmeyer also serves as a director of Advancis Pharmaceutical Corporation, Baxter International, Inc. and GenVec, Inc. Dr. Hockmeyer was recognized, in 1998, by the University of Florida as a Distinguished Alumnus and in 2002 was awarded a Doctor of Science honoris causa from Purdue University. Dr. Hockmeyer holds a B.S. from Purdue University and a Ph.D. from the University of Florida.
Cramb, Charles Charles W. Cramb is Director of Idenix Pharmaceuticals, Inc. Mr. Cramb has served as the vice chairman, chief finance and strategy officer of Avon Products, Inc., a global beauty products company since September 2007. Mr. Cramb joined The Avon Company in November 2005 and previously served as executive vice president finance and technology and chief financial officer. Prior to joining The Avon Company, Mr. Cramb served as the chief financial officer at The Gillette Company, a worldwide consumer products company, from July 1997 to November 2005. From July 1995 to July 1997, Mr. Cramb served as a corporate vice president and corporate controller of The Gillette Company. He is also a member of the board of directors of Tenneco Inc. Mr. Cramb holds a B.A. from Dartmouth College and a M.B.A. from the University of Chicago.
Pelzer, Robert Robert E. Pelzer is Director of Idenix Pharmaceuticals, Inc. Mr. Robert Pelzer is Director of Idenix Pharmaceuticals, Inc. He is general counsel of Novartis Pharmaceuticals Division, a part of the Novartis Group, a multinational group of companies specializing in the research, development, manufacture, sale and distribution of innovative healthcare products. Prior to this appointment at Novartis in March 2002 to August 2008, Mr. Pelzer was general counsel at DuPont Pharmaceuticals Company from 1998 to December 2001. Prior to that time, Mr. Pelzer held various positions with The DuPont Company. Mr. Pelzer holds degrees in Commerce and in Law from the University of Alberta. He is admitted as barrister and solicitor in the Province of Alberta, Canada, and as Solicitor in England and Wales.
Pollard-Knight, Denise Denise Pollard-Knight is Director of Idenix Pharmaceuticals, Inc. Dr. Pollard-Knight has served since April 2004 as managing director of Nomura Phase4 Ventures, an affiliate of Nomura International plc, a Japanese financial institution. From January 1999 to March 2004, Dr. Pollard-Knight served as head of Healthcare Private Equity at Nomura International plc. From January 1997 to January 1999, Dr. Pollard-Knight was a member of Rothschild Asset Management Ltd., an investment management firm. Dr. Pollard-Knight holds a Ph.D. and BSc (Hons) from the University of Birmingham in England. Dr. Pollard-Knight completed postdoctorate work as a Fulbright Scholar at the University of California, Berkeley.
Projan, Steven Steven Projan, Ph.D. is Director of Idenix Pharmaceuticals, Inc. Dr. Projan has served as a director since February 2009. Dr. Projan has served as vice president, global head of infectious diseases for the Novartis Institute for Biomedical Research, Inc. since September 2008. Prior to joining Novartis, from 1993 to August 2008, Dr. Projan held several positions at Wyeth Pharmaceuticals, including his most recent position as vice president of biological technologies. Dr. Projan holds a Ph.D. in molecular genetics from Columbia University.

Basic Compensation

Name Fiscal Year Total
Sommadossi, Jean-Pierre 2,602,690
Renaud, Ronald 802,741
Weidenbruch, John 628,348
Standring, David 569,738
Mayers, Douglas 665,534
Fanning, Paul --
Hodgson, Thomas --
Hockmeyer, Wayne --
Cramb, Charles --
Pelzer, Robert --
Pollard-Knight, Denise --
Projan, Steven --
As Of 30 Dec 2008

Insider Trading

Name Shares Traded Price
HODGSON THOMAS R 10,387 $2.12
HODGSON THOMAS R 15,000 $2.15
WEIDENBRUCH JOHN 20,000 $1.89
STANDRING DAVID N 15,000 $1.00
NOVARTIS AG 3,571 $2.41
NOVARTIS AG 2,451 $2.62
NOVARTIS AG 5,444 $2.41
NOVARTIS AG 4,747 $4.05
SOMMADOSSI JEAN PIERRE 110,000 $8.00
NOVARTIS AG 4,654 $2.93
NOVARTIS AG 924 $2.41
RENAUD RONALD C JR 4,587 $4.50
WEIDENBRUCH JOHN 2,937 $4.59
WEIDENBRUCH JOHN 1,900 $4.52
RENAUD RONALD C JR 10,413 $4.55
WEIDENBRUCH JOHN 9,722 $4.55
MAYERS DOUGLAS L 30,000 $4.45
WEIDENBRUCH JOHN 441 $4.54
» Full list on Insider Trading
view people for: